Evidence map›Paper›PMID 30748002›Full record

ArticleCancer2019

Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma.

Nicholas C J Lee, Jacqueline R Kelly, Yi An, Henry S Park, Benjamin L Judson, Barbara A Burtness, Zain A Husain

Open access · bronzeAbstract read
In one paragraph

Article in Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Nicholas C J LeeDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-7478-8545
Jacqueline R KellyDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-6789-3689
Yi AnDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.
Henry S ParkDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-9366-8514
Benjamin L JudsonDivision of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, Connecticut.
Barbara A BurtnessDivision of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0003-4660-1859
Zain A HusainDepartment of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.
Yale University · USSunnybrook Health Science Centre · CA

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Short Term Research Training: Students in Health Professional SchoolsT35DK104689 · NIDDK · YALE UNIVERSITY · PI LLOYD G CANTLEY, Sarwat I Chaudhry · 2015 to 2026
$2.6M
NCATS NIH HHS UL1 TR001863NIDDK NIH HHS T35 DK104689
6 · The paper itself

Abstract

backgroundTreatment at high-volume surgical facilities (HVSFs) provides a survival benefit for patients with head and neck squamous cell carcinomas (HNSCCs); however, it is unknown what role postoperative radiation therapy (PORT) plays in achieving the improved outcomes.

methodsFrom the National Cancer Database, 6844 patients with locally advanced invasive HNSCCs of the oral cavity, oropharynx, larynx, and hypopharynx who underwent definitive surgery with PORT between 2004 and 2013 were identified. HVSFs were those in the top percentile for annual case volume during this period.

resultsThe median follow-up was 54 months. Compared with a lower volume surgical facility (LVSF), an HVSF improved 5-year overall survival (OS; 57.7% at HVSFs vs 52.5% at LVSFs; P = .0003). Overall, 31.6% of the patients changed their radiation therapy (RT) facility after surgery, with this being more common at HVSFs (39.1% vs 28.9% at LVSFs; P < .001). Among those patients undergoing surgery at an HVSF, remaining at the same facility for RT improved 5-year OS (63.1% vs 49.3% with a facility change; P < .0001). A propensity score-matched cohort of patients treated at HVSFs confirmed the improved 5-year OS when patients remained at the treating HVSF for RT (59.2% vs 50.7% with a facility change; P = .005). In a multivariate analysis, treatment at an HVSF and remaining there for RT resulted in a reduced hazard of death (hazard ratio, 0.81; 95% confidence interval, 0.69-0.94; P = .006).

conclusionsThe survival benefit associated with HVSFs persists only when patients remain at the facility for RT, and this suggests that facility specialization and/or high-volume PORT may assist in driving the OS improvement.

Indexed as

Databases, FactualFemaleFollow-Up StudiesHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm InvasivenessPostoperative CarePrognosisRadiotherapy, AdjuvantSquamous Cell Carcinoma of Head and NeckSurvival Ratehead and neck cancerhigh-volume facilityhypopharynxlarynxoral cavityoropharynxradiation therapyvolume

Identifiers

PMID30748002
PMCPMC6541535
OpenAlexW2915036904

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.